NCT01307592Unknown2 期
Pilot Study of GC. (Gemcitabine-Rituximab-Oxaliplatin Combination) Given Every 14 Days With Maintenance Lenalidomide for the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Auxilio Mutuo Cancer Center2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2011年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 70
- 试验地点
- 2
- 主要终点
- Rate of conversion to complete response (CR) after switching to lenalidomide
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, oxaliplatin, and , work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Lenalidomide may stop the growth of non-Hodgkin lymphoma by blocking blood flow to the cancer. Giving rituximab and chemotherapy together with lenalidomide may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab, gemcitabine hydrochloride, and oxaliplatin together with lenalidomide works in treating patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.
详细描述
OBJECTIVES:
Primary
- To determine the rate of conversion to complete response (CR) after switching to lenalidomide in patients with relapsed or refractory, aggressive non-Hodgkin lymphoma whose maximum response to gemcitabine hydrochloride, rituximab, and oxaliplatin is a partial response (PR).
Secondary
- To determine the overall survival of these patients treated with this regimen.
- To determine the progression-free survival of patients with CR and PR.
- To determine the treatment-related toxicity of this regimen combination in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed aggressive non-Hodgkin lymphoma, including any of the following subtypes:
- •Follicular large cell lymphoma
- •Diffuse large cell lymphoma
- •Peripheral T-cell lymphoma
- •Transformed lymphoma
- •Lymphoblastic lymphoma
- •Burkitt or Burkitt-like lymphoma
- •Refractory or relapsed disease meeting the following criteria:
- •Patients who either did not respond to prior therapy or whose best response was partial response after ≥ 4 courses of chemotherapy
- •Histologic confirmation of relapsed or refractory disease is desirable but not mandatory and will be left to the discretion of the investigator
- •Must have evaluable or measurable disease
- •Patients who are candidates for stem cell or bone marrow transplantation allowed
- •No CNS involvement by lymphoma
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-3
- •Absolute neutrophil count ≥ 1,000/mm³ (unless due to marrow infiltration by lymphoma)
- •Platelet count ≥ 100,000/mm³ (unless thrombocytopenia is due to marrow infiltration by lymphoma)
- •Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless liver is involved with lymphoma, hemolysis, or Gilbert syndrome)
- •Serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥ 30 ml/min (unless creatinine elevation is due to lymphoma)
- •ALT ≤ 2 times ULN (≤ 5 times ULN if liver metastasis is involved with lymphoma)
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective double-method contraception for ≥ 28 days before, during, and for ≥ 28 days after completion of study therapy
- •Men must use latex condoms even after a successful vasectomy
- •Must be enrolled in the mandatory RevAssist® program and be willing to comply with its requirements
- •No neurosensory or neuromotor dysfunction ≥ grade 3
- •No known HIV positivity or active hepatitis B or C (hepatitis B surface antigen positivity or hepatitis C RNA positivity)
- •No known hypersensitivity to thalidomide or erythema nodosum characterized by desquamating rash while taking thalidomide or other similar drugs
- •No history of allergy to platinum or any of its derivatives or E. coli-derived products
- •No other malignancies within the past 5 years, except treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or any surgically cured malignancy from which the patient has been disease-free for ≥ 5 years
- •No NYHA class III-IV congestive heat failure (no symptoms on less than ordinary exertion or at rest)
- •No uncontrolled or intercurrent disease, including any of the following:
- •Arrhythmias
- •Angina pectoris
- •Active infection or fever > 38.2 C (unless due to lymphoma)
- •No serious medical condition, laboratory abnormality, or psychiatric illness that would place patient at risk in study or confound ability to interpret study data
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •No prior gemcitabine hydrochloride, oxaliplatin, or lenalidomide
- •Prior rituximab allowed
- •No more than 4 prior regimens of chemotherapy allowed, including stem cell or bone marrow transplantation
- •More than 2 weeks since prior and no concurrent anticancer therapy, including radiotherapy, hormonal therapy, or surgery
- •More than 3 weeks since prior chemotherapy or radiotherapy
- •More than 28 days since prior and no other concurrent investigational drug trial or investigational agent
- •Able to take aspirin (81 mg or 325 mg) daily or low molecular weight heparin as prophylactic anticoagulation
- •No concurrent thalidomide
排除标准
- 未提供
结局指标
主要结局
Rate of conversion to complete response (CR) after switching to lenalidomide
次要结局
- Overall survival
- Rate of conversion to partial response and CR of non-responders treated with lenalidomide
- Progression-free survival
- Safety of this regimen combination
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary CancerExtrahepatic Bile Duct CancerGallbladder CancerPeriampullary AdenocarcinomaPancreatic CancerSmall Intestine CancerLiver CancerNCT00987766Vanderbilt-Ingram Cancer Center28
Unknown
3 期
Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic AdenocarcinomaPancreatic CancerNCT00075452GERCOR - Multidisciplinary Oncology Cooperative Group
已完成
3 期
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by SurgeryExtrahepatic Bile Duct CancerGallbladder CancerLiver CancerNCT01313377UNICANCER190
Unknown
1 期
Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With IrinotecanColorectal CancerNCT00496704Yonsei University56
Unknown
2 期
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00274859GERCOR - Multidisciplinary Oncology Cooperative Group45